On November 4, 2025 Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, reported that its abstract titled "Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME) and N-ally Noroxymorphone (NaN) Compared to Tamoxifen (TAM) and Abemaciclib (ABE)", has been accepted and will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Thursday, December 11, 2025.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In a head-to-head comparison with standard-of-care therapies Tamoxifen and Abemaciclib (i.e., Verzenio), a single intratumoral injection of Zeta-BC-007 significantly outperformed both agents. Mice treated with Zeta-BC-007 containing NME + NaN + ABE showed a 66% reduction in tumor volume and complete absence of tumor activity by day 60, while all mice in the TAM and ABE groups succumbed to disease.
"Zeta-BC-007 represents a significant leap forward in intratumoral cancer therapy. By combining a novel molecular entity with synergistic therapeutics in a lipid-based hydrogel, we’ve demonstrated not only superior tumoricidal activity but also extended survival in preclinical models. These results reinforce our commitment to developing localized, non-systemic treatments that challenge the limitations of conventional cancer care."
— Bryan S. Margulies, PhD, Co-founder and CSO, Zetagen Therapeutics
"These results mark a pivotal moment in our journey to redefine primary breast cancer treatment," said Joe C. Loy, CEO of Zetagen Therapeutics. "the ability of Zeta-BC-007 to deliver potent tumoricidal effects through a single localized injection — without systemic toxicity — represents a new frontier in oncology. We believe this platform has the potential to transform how solid tumors are treated."
Presentation Details:
Abstract Number: 3638
Presentation Number: PSA-06-30
Presentation Title: Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME) and N-ally Noroxymorphone (NaN) Compared to Tamoxifen (TAM) and Abemaciclib (ABE)
Poster Presentation: Thursday, December 11, 2025, 5:00-6:30pm CST
About ZetaPrime (Zeta-PBC-007)
ZetaPrime is a neo-adjuvant treatment for primary HR+ breast cancer, engineered for a locoregional administration following diagnosis. Utilizing a proprietary hydrogel-like lipid carrier, the novel formulation enables controlled release of multiple small molecules — with one being our novel molecular entity coupled with any other fat-soluble drugs; including other companies CDK4 or CDK4/6 protein inhibitors or any anticancer therapeutic. Designed for solubility within adipose tissue, ZetaPrime is a paradigm-shifting intratumoral approach to adjuvant therapy that targets primary breast cancer, aiming to mitigate off-target effects, reduce necessity for lumpectomies and mastectomies, postpone radiation exposure, and enhance patient survival.
(Press release, Zetagen Therapeutics, NOV 4, 2025, View Source [SID1234659380])